Skip to content

Palvella Therapeutics PVLA Accrued Liabilities And Other Liabilities Current

Accrued Liabilities And Other Liabilities Current at other companies

Kyndryl Holdings logo
Kyndryl HoldingsKD
$903M+98.9%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$42.85M+27.7%
10x Genomics, Inc. logo
10x Genomics, Inc.TXG
$33.68M-26.0%
Veeco Instruments logo
Veeco InstrumentsVECO
$52.04M-16.4%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$28.58M+7.7%
Enliven Therapeutics logo
Enliven TherapeuticsELVN
$9.85M-20.7%

Other financials

Income statement

See full
Revenue$53.0K-97.3%
Operating income-$14.9M-88.7%
Net income-$15.8M-92.6%
EPS (diluted)-$1.20-62.2%

Balance sheet

See full
Cash & equivalents$206.4M+173%
Total debt$584.0K
Total equity$232.3M+318%
Total assets$263.8M+232%

Cash flow

See full
Operating cash flow-$10.9M-60.5%
CapEx--100%
Free cash flow-$2.7M+72.0%

Valuation

See full
Market cap$1.7B+468%
Enterprise value$1.5B
P/S41.6×

Profitability

See full
Operating margin-183.2%-13.5pp
Net margin71.7%+40.4pp
FCF margin-99.8%-34.2pp

Returns & leverage

See full
Return on equity-34.2%
Debt / equity
Current ratio28.9×+20.0×

Where this comes from

Reported directly by Palvella Therapeutics in its filing.

Tagged under the XBRL concept pvla:AccruedLiabilitiesAndOtherLiabilitiesCurrent.

The official record: Palvella Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Palvella Therapeutics's accrued liabilities and other liabilities current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Palvella Therapeutics's accrued liabilities and other liabilities current?
Palvella Therapeutics (PVLA) reported accrued liabilities and other liabilities current of $3.46M in Q1 2026.
How has Palvella Therapeutics's accrued liabilities and other liabilities current changed year-over-year?
Palvella Therapeutics's accrued liabilities and other liabilities current increased by 35.1% year-over-year, from $2.56M to $3.46M.
What is the long-term trend for Palvella Therapeutics's accrued liabilities and other liabilities current?
Over 2 years (2023 to 2025), Palvella Therapeutics's accrued liabilities and other liabilities current has grown at a 74.8% compound annual growth rate (CAGR), from $1.42M to $4.35M.
What does accrued liabilities and other liabilities current mean?
This balance captures short-term obligations for goods or services received but not yet invoiced or paid, including accrued payroll, professional fees, and clinical trial expenses. It reflects the company's immediate operational commitments and short-term working capital requirements. Monitoring this figure provides insight into the company's near-term cash outflow obligations and operational scale.